KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesLong-Term Debt RepaymentsNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Gains from Investment Securities (2017 - 2025)

Alnylam Pharmaceuticals (ALNY) has disclosed Gains from Investment Securities for 13 consecutive years, with $18.8 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Gains from Investment Securities rose 102.17% year-over-year to $18.8 million, compared with a TTM value of $21.2 million through Dec 2025, up 127.68%, and an annual FY2025 reading of $21.2 million, up 127.68% over the prior year.
  • Gains from Investment Securities was $18.8 million for Q4 2025 at Alnylam Pharmaceuticals, up from $1.3 million in the prior quarter.
  • Across five years, Gains from Investment Securities topped out at $18.8 million in Q4 2025 and bottomed at -$8.7 million in Q2 2025.
  • Average Gains from Investment Securities over 5 years is $2.6 million, with a median of $1.6 million recorded in 2024.
  • The sharpest move saw Gains from Investment Securities skyrocketed 3130.3% in 2022, then tumbled 390.29% in 2023.
  • Year by year, Gains from Investment Securities stood at -$165000.0 in 2021, then plummeted by 130.91% to -$381000.0 in 2022, then crashed by 390.29% to -$1.9 million in 2023, then skyrocketed by 598.34% to $9.3 million in 2024, then skyrocketed by 102.17% to $18.8 million in 2025.
  • Business Quant data shows Gains from Investment Securities for ALNY at $18.8 million in Q4 2025, $1.3 million in Q3 2025, and -$8.7 million in Q2 2025.